Liver bacteria may hold key to new alcoholic hepatitis treatments
NCT ID NCT06307964
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at bacteria found in the liver, blood, and stool of 50 people with severe alcoholic hepatitis. Researchers want to see if these bacteria are linked to how well patients respond to treatment and their overall survival. The goal is to find new ways to treat this serious liver disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2024
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
A prospective observational multicentric cohort will be conducted at Croix Rousse Hospital (Lyon, France), in the Hepatology and Intensive Care Units. Fifty consecutive patients hospitalized in either of these units for clinical suspicion of alcoholic hepatitis and indication for transjugular liver biopsy will be included.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients suffering from alcoholic liver disease and clinical suspicion of alcoholic hepatitis (subacute jaundice, heavy alcohol consumption active or weaned for ≤ 3 months, modified Maddrey score ≥32) and indication for diagnostic transjugular liver biopsy; * Non-objection obtained from the patient or trusted person in case of impaired judgment or consciousness before performing liver biopsy; * Aged ≥ 18 years at the time of study entry; Exclusion Criteria: * Patients who were treated with antibiotics or probiotics between the 15th day and 72 hours prior to liver biopsy, with the exception of antibiotics used for the prophylaxis of ascites infection or hepatic encephalopathy * Contraindication to transjugular liver biopsy (hepatocellular carcinoma on predicted puncture site) * Pregnant, parturient or breast-feeding women * Persons deprived of their liberty by judicial or administrative decision * Adults under legal protection (guardianship, curators)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alcoholic hepatitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hospices Civils de Lyon, Croix Rousse Hospital
RECRUITINGLyon, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves may replace the needle in liver scarring tests
- Ultrasound may replace invasive test for dangerous liver complication
- A blood test could map how the liver heals after alcohol damage
- Could a wearable zapper quiet cirrhosis pain without drugs?
- A needle through the gut could replace the standard liver pressure test
- Can two experimental drugs be used safely in people with cirrhosis?